---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-019416"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2024-02-23T23:59:59+00:00"
generated_at: "2026-06-05T17:07:17.440302+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Atara CMO Joshi departs; consulting deal includes $180K milestone on tabelecleucel BLA approval

## Summary
- EVP, Chief Medical Officer Dr. Joshi terminated Feb 2, 2024 as part of reduction in force.
- Entered consulting agreement Feb 22, 2024: $3,000 monthly fee plus $300/hr for excess hours.
- Outstanding RSU equity awards will continue vesting during consulting term.
- Eligible for $180,000 payment upon FDA approval of tabelecleucel BLA.
- Consulting arrangement runs through January 31, 2025.

## SEC filing metadata
- accession: 0000950170-24-019416
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2024-02-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000095017024019416/0000950170-24-019416-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000095017024019416/atra-20240222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-019416
- JSON: https://secwatch.observer/filing/0000950170-24-019416.json
- Plain text: https://secwatch.observer/filing/0000950170-24-019416.txt

## Key facts
- Executive change
  Dr. Joshi was terminated as Executive Vice President, Chief Medical Officer at Atara Biotherapeutics, Inc..
  - Action: terminated
  - Role: Executive Vice President, Chief Medical Officer
  source text: the employment of the Company’s Executive Vice President, Chief Medical Officer would terminate effective as of February 2, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017024019416/0000950170-24-019416-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.